Pfizer Inc
NYSE: PFE
$28.88
+$0.43 (+1.5%)
Real Time Data Delayed 15 Min.
PFE Articles
Pfizer Inc. (NYSE: PFE) has a big day ahead of it. While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic versions of the statin drug competitors....
Published:
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a drug company tries to develop that...
Published:
The supercommittee appears unlikely to settle on a deficit agreement. (Reuters) A senior Chinese official says he expects the global recession to last for some time. (Reuters) Spain’s center-right...
Published:
Some companies just want to keep bringing on new share buybacks whether they work or not. Some are to stop dilution from acquisitions or employee stock options, while others are to reduce the float...
Published:
The economic choppiness is coming to a head with the age of dividend hikes. The pressure is going to remain for companies to continue returning capital to shareholders while also looking for...
Published:
Last Updated:
George Papandreou convinces the Greek cabinet of the virtues of a national referendum on budget cuts, but he now faces the leaders of France and Germany. (Reuters) The FBI may investigate the fall of...
Published:
The markets are beyond jittery. From a massively overbought market discounting a recession entirely back to a market dominated by the woes of Europe. The Europeans cannot get their bailouts...
Published:
Last Updated:
Earnings season is still running strong and the economic readings keep coming out as well. As we come to the end of October, there is going to be plenty of news coming down the pipe. We also have...
Published:
Last Updated:
Short sellers moved out of stocks that have fallen recently. Perhaps they believe there will be a large rally in the market. There is little else to make the shares of companies with poor earnings...
Published:
Novartis (NYSE: NVS) said it would cut 2,000 workers and outsource some functions to companies that will do the work for less than it can. Novartis will take a restructuring charge of $300 million....
Published:
A company can spend billions of dollars on R&D and get little respect as an innovator. Even though that is the conclusion of a new study by Booz & Co., the conclusion is misleading. Booz...
Published:
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit...
Published:
Last Updated:
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and more...
Published:
Last Updated:
The 30-Year Treasury auction, the so-called Long Bond, had a strong participation for what is technically a 29-year and 11-month bond. The participation rate was strong enough that this still shows...
Published:
Last Updated:
These are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research calls. Alkermes, Inc. (NASDAQ: ALKS) Removed from US 1 List but...
Published:
Last Updated: